Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.
Vicebio has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
Vicebio's investors include TCG Crossover, Medicxi, venBio Partners, Goldman Sachs Alternatives, Avoro Ventures.
Vicebio is headquartered in London, United Kingdom.
Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.
Vicebio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vicebio — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/vicebio. Accessed November 14, 2026.
VCBacked. (2024). Vicebio — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/vicebio
{{cite web |title=Vicebio — Funding & Investors |url=https://www.vcbacked.co/company/vicebio |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Vicebio? Request a listing update